Dynavax Technologies | DVAX - Interest Income


Dynavax Technologies reported $6.8M in Interest Income for its fiscal quarter ending in June of 2025.





Interest Income Change Date
AbbVie USD 72M 10M Sep/2025
Adma Biologics USD 376K 24K Sep/2025
AstraZeneca USD 68M 16M Jun/2025
Biogen USD 32.3M 8.4M Jun/2025
BioMarin Pharmaceutical USD 18.83M 186K Jun/2025
Dynavax Technologies USD 6.8M 941K Jun/2025
Gilead Sciences USD 73M 21M Jun/2025
Glaxosmithkline GBP 26M 24M Sep/2025
Merck USD 96M 27M Sep/2025
Pfizer USD 0.62 156M Sep/2025
Regeneron Pharmaceuticals USD 175.1M 300K Sep/2025
Sarepta Therapeutics USD 7.14M 3.05M Jun/2025
Vertex Pharmaceuticals USD 122.4M 1.5M Jun/2025